Related Experiment Video
Updated: May 18, 2026
07:51
Refined Murine Model of Idiopathic Pulmonary Fibrosis
Published on: June 17, 2025
Idiopathic pulmonary fibrosis.
Jessica M Adkins1, Harold R Collard
1Department of Medicine, Division of Pulmonary and Critical Care Medicine, University of California, San Francisco, San Francisco, CA 94143, USA.
Seminars in Respiratory and Critical Care Medicine
|September 25, 2012
Summary
Idiopathic pulmonary fibrosis (IPF) is a progressive lung disease with a poor prognosis. Current management focuses on comprehensive care, as novel diagnostics and treatments emerge.
Area of Science:
- Pulmonology
- Interstitial Lung Diseases
- Fibrotic Lung Disease
Background:
- Idiopathic pulmonary fibrosis (IPF) is a progressive, chronic fibrosing interstitial lung disease primarily affecting older adults.
- IPF has a dire prognosis, with a median survival of 3-5 years post-diagnosis due to respiratory failure.
- The pathogenesis and natural history of IPF are complex, variable, and not fully understood.
Purpose of the Study:
- To provide an overview of the current state of idiopathic pulmonary fibrosis (IPF) diagnosis and management.
- To highlight emerging advancements in IPF research and clinical practice.
- To emphasize the importance of comprehensive patient management strategies.
Main Methods:
- Review of current literature on IPF pathogenesis, diagnosis, prognosis, and treatment.
- Discussion of emerging diagnostic tools, prognostic models, and therapeutic agents.
- Emphasis on current clinical management strategies including symptom control and comorbidity management.
Main Results:
- IPF remains a disease with limited treatment options, primarily lung transplantation.
- Novel diagnostic biomarkers and prognostic models are under development.
- Clinical trials are exploring new drug agents that may significantly alter disease management.
Conclusions:
- Despite challenges, advancements in IPF research offer hope for improved patient outcomes.
- Comprehensive management, including symptom control, comorbidity management, and patient support, is crucial.
- The future of IPF management will likely involve a combination of novel therapies and integrated care approaches.
Related Concept Videos
01:23Chronic Obstructive Pulmonary Disease I: Introduction
Chronic obstructive pulmonary disease is a common, preventable, and treatable respiratory disorder characterized by persistent symptoms and progressive airflow limitation. This limitation results from a combination of small-airway disease (obstructive bronchiolitis) and parenchymal destruction (emphysema), both driven by chronic inflammation from exposure to harmful particles or gases.The disease includes two main pathological entities: emphysema, marked by destruction of alveolar walls and...
01:23Chronic Obstructive Pulmonary Disease II: Emphysema
Emphysema, a major phenotype of chronic obstructive pulmonary disease (COPD), is characterized by irreversible destruction of alveolar walls and permanent enlargement of distal airspaces. Unlike chronic bronchitis, which primarily affects the airways, emphysema predominantly involves the lung parenchyma, where structural damage leads to airflow limitation.PathophysiologyIt most commonly results from prolonged exposure to cigarette smoke and other toxic gases, particularly cigarette smoke.
01:20Chronic Obstructive Pulmonary Disease-II: Pathophysiology
Chronic Obstructive Pulmonary Disease (COPD) pathophysiology is intricate and multifaceted, involving a complex interplay of physiological processes. Understanding these mechanisms is crucial for effectively managing and treating COPD. Here is an in-depth look at the critical elements in the pathophysiology of COPD:
Chronic Inflammation
Chronic Inflammation
01:24Chronic Obstructive Pulmonary Disease III: Chronic Bronchitis Features
Chronic bronchitis is a key phenotype of chronic obstructive pulmonary disease (COPD), characterized by airway-centered inflammation and mucus overproduction. It develops from long-term exposure to harmful particles or gases, most commonly cigarette smoke, which triggers a persistent inflammatory response.Cellular and Structural ChangesInflammation initially affects the large bronchi and later the smaller airways, with infiltration by immune cells, including neutrophils, macrophages, and...
01:20Chronic Obstructive Pulmonary Disease-I: Introduction
Chronic Obstructive Pulmonary Disease (COPD) is a long-lasting respiratory condition requiring continuous attention and care. It is a progressive lung disease that leads to breathing challenges due to airflow obstruction. It manifests as persistent respiratory symptoms and restricted airflow resulting from abnormalities in the airways and alveoli, usually due to long-term exposure to harmful particles or gases. COPD mainly consists of two primary conditions: emphysema and chronic bronchitis.
01:30Pulmonary Hypertension: Classification and Pathogenesis
Pulmonary hypertension (PH) is a severe health condition in which the mean pulmonary arterial pressure increases to 25 mmHg or more, even when the body is at rest. This high pressure in the blood vessels that transport blood from the heart to the lungs can cause various symptoms, including shortness of breath, can lead to right heart failure, and significantly affect the overall quality of life.
There are various classifications for PH, each relating to different underlying causes and also...
There are various classifications for PH, each relating to different underlying causes and also...